Skip to main content
Norris Cotton Cancer Center
In This Section

New Clinical Trials for May 2015

Konstantin Dragnev
Cancer Mechanisms

A Phase III, double-blind, randomized study to assess the efficacy and safety of AZD9291 versus a standard of care epidermal growth factor receptor tyrosine kinase inhibitor as first-line treatment in patients with epidermal growth factor receptor mutation positive, locally advanced or metastatic non-small cell lung cancer

Camilo Fadul
Immunology and Cancer Immunotherapy

Novartis Pharmaceuticals
Early-Phase study to assess tumor pharmacokinetics and efficacy of the CDK4/6 inhibitor LEE011 in patients with recurrent glioblastoma or anaplastic glioma

J Marc Pipas
Molecular Therapeutics

A randomized, double-blind study of ruxolitinib or placebo in combination with regorafenib in subjects with relapsed or refractory metastatic colorectal cancer